EII.F

Healthcare Drug Manufacturers - Specialty & Generic

Eisai Co., Ltd.

€26.13

-0.04 -0.15% today

Price History

Not enough data

Key Stats

Market Cap

7.37B

Avg Volume

P/E (TTM)

33.50

EPS

€0.78

52W High

€28.36

52W Low

€19.71

Div. Yield

612.3%

Valuation

Forward P/E

22.14

P/B Ratio

1.45

P/S Ratio

0.01

EV/EBITDA

-0.07

EV/Revenue

-0.01

Margins

Gross Margin 76.7%

Operating Margin 10.6%

Net Margin 4.9%

EBITDA Margin 11.2%

Growth & Returns

Revenue Growth (YoY)

15.6%

Earnings Growth (YoY)

26.0%

Earnings Growth (QoQ)

26.0%

Return on Equity

5.0%

Return on Assets

2.4%

Liquidity & Leverage

Current Ratio

2.24

Quick Ratio

1.44

Debt / Equity

0.29

Total Cash

311.74B

Total Debt

271.34B

About

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.